Home / Stocks / Vijaya Diagnostic Cen Ltd
VIJAYA

Vijaya Diagnostic Cen Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,510.6

Change

-23.0 (-1.5%)

Open

₹1,536.0

Prev. Close

₹1,533.6

Day High

₹1,553.7

Day Low

₹1,500.0

Volume Analysis

Traded

133,115

Delivered

34,301

Delivery %

25.77%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (43.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (26.6%)
  • •Strong 3-year revenue growth (21.0%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,596.56 ₹1,575.13 ₹1,542.86 ₹1,521.43 ₹1,489.16 ₹1,467.73 ₹1,435.46
Fibonacci ₹1,575.13 ₹1,554.62 ₹1,541.94 ₹1,521.43 ₹1,500.92 ₹1,488.24 ₹1,467.73
Camarilla ₹1,525.37 ₹1,520.45 ₹1,515.52 ₹1,521.43 ₹1,505.68 ₹1,500.76 ₹1,495.83

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+44.92%

1 Week

+6.71%

1 Month

+11.62%

3 Months

+0.41%

6 Months

+23.1%

1 Year

+49.36%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹197.38

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

17.26%

Net margin 22.39% × asset turnover 0.47x × equity multiplier 1.64x

Company Overview

Sector

Healthcare

Market Cap

₹14,524 Cr

P/E (TTM)

71.3

ROE

18.9%

Book Value

₹103.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 15 Nov 2026. Not investment advice.

TopFund Analysis

Vijaya Diagnostic Cen Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 71/100. The strongest factor is Business Quality (91/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (43.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

71/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

89

Growth

89

Valuation

0

Cash Flow

87

Corporate Governance

63

Momentum

75

Institutional Ownership

62

Business Quality

91

Risk & Volatility

82

Liquidity

50

From Screener.in

  • −Stock is trading at 13.7 times its book value

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of the Earnings Call for Q2 FY27 Financial Results held on November 04, 2026

Newspaper Publication of the Financial Results for the quarter and half year ended September 30, 2026

Company shared audio recording of Q2 FY2027 earnings conference call held November 4, 2026.

Investor Presentation on unaudited Financial Results for Quarter and Half Year Ended September 30, 2026

Vijaya Diagnostic Centre reported Q2 FY27 revenue of Rs 2,553.9 million, PAT of Rs 594.7 million, and acquired Arya Wellness Centre.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 139 133 155 156 183 169 173 188 202 205 219 231 255
Expenses + 82 80 92 95 107 102 104 115 120 119 124 132 143
Operating Profit 57 52 63 61 76 67 69 74 82 86 96 99 113
OPM % 41.0% 39.0% 41.0% 39.0% 42.0% 40.0% 40.0% 39.0% 41.0% 42.0% 44.0% 43.0% 44.0%
Other Income + 7 3 3 4 5 5 5 7 6 5 2 9 5
Interest 6 6 6 6 6 7 7 7 8 9 9 11 11
Depreciation 14 15 16 17 17 18 19 21 22 24 24 25 27
Profit before tax 45 35 44 42 57 47 47 52 58 58 64 71 79
Tax % 25.0% 25.0% 23.0% 25.0% 26.0% 24.0% 26.0% 26.0% 25.0% 26.0% 25.0% 25.0% 25.0%
Net Profit + 34 26 34 32 42 35 35 39 43 43 48 53 59
EPS in Rs 3 3 3 3 4 3 3 4 4 4 5 5 6
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 15 17 28 29 32 27 12 20 10 21 27 23 27

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 251 293 339 377 462 459 548 681 814 911
Expenses + 171 184 206 211 259 277 327 408 477 518
Operating Profit 80 108 133 166 204 182 221 273 337 393
OPM % 32.0% 37.0% 39.0% 44.0% 44.0% 40.0% 40.0% 40.0% 41.0% 43.0%
Other Income + 7 10 15 12 13 14 19 17 21 21
Interest 5 14 15 15 16 21 24 27 33 40
Depreciation 26 40 49 50 53 62 57 71 92 101
Profit before tax 55 65 83 112 147 114 159 193 233 273
Tax % 37.0% 29.0% 25.0% 24.0% 25.0% 25.0% 25.0% 26.0% 26.0% —
Net Profit + 35 46 63 85 111 85 120 144 173 204
EPS in Rs 3 5 6 8 11 8 12 14 17 20
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 9.0% 12.0% 9.0% 14.0% 12.0% —
Sales growth — 17 16 11 23 -1 19 24 19 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 157 203 270 354 458 535 647 789 947 1,047
Borrowings + 33 146 161 141 183 248 259 320 423 509
Other Liabilities + 39 53 46 41 62 61 66 155 127 167
Total Liabilities 234 406 482 541 713 853 983 1,274 1,507 1,733
Fixed Assets + 119 259 272 268 370 524 742 865 1,069 1,185
CWIP 3 3 10 9 34 28 9 70 35 33
Investments 73 69 55 28 54 139 109 185 228 304
Other Assets + 39 76 146 236 255 163 123 154 174 212
Total Assets 234 406 482 541 713 853 983 1,274 1,507 1,733
Equity Capital 5 5 5 5 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 62 91 106 130 158 165 183 224 271
Cash from Investing Activity + -98 -90 -31 -130 -123 -110 -141 -182 -174
Cash from Financing Activity + -8 -7 -30 -49 -31 -42 -45 -52 -69
Net Cash Flow -44 -6 46 -49 4 13 -2 -9 27
Free Cash Flow 32 31 69 98 37 40 99 132 91
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 103 101 98 97 97 105 98 97 96

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.87% → 52.46%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 5.36% 5.03% 4.5% 4.49% 3.92% 3.86% 3.73% 3.77% 3.7% 4.17% 4.22% 4.38%
Promoters 54.87% 54.06% 53.92% 53.91% 53.91% 53.05% 52.63% 52.6% 52.6% 52.51% 52.51% 52.46%
FII 19.95% 20.09% 20.08% 18.14% 17.54% 19.36% 19.56% 18.27% 15.1% 13.38% 11.65% 10.67%
DII 19.82% 20.8% 21.49% 23.45% 24.62% 23.72% 24.07% 25.34% 28.6% 29.93% 31.61% 32.49%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Vijaya Diagnostic Cen Ltd (this stock) 14,524 71.3 13.69 18.9%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%
Corona Remedies Limited 14,010 63.6 17.34 29.5%
Sudeep Pharma Limited 13,545 71.9 14.14 25.2%
Indegene Limited 15,640 36.7 4.67 14.4%
Marksans Pharma Limited 13,347 23.8 4.0 15.2%
Natco Pharma Ltd. 15,881 19.1 1.5 17.1%

Which Mutual Funds Hold Vijaya Diagnostic Cen Ltd?

Frequently Asked Questions about Vijaya Diagnostic Cen Ltd

Community Sentiment

What are other investors saying about Vijaya Diagnostic Cen Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.